Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Wet Macular Degeneration | 30 | 2024 | 162 | 10.720 |
Why?
|
Macular Degeneration | 40 | 2024 | 1008 | 7.220 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 37 | 2024 | 664 | 6.930 |
Why?
|
Visual Acuity | 95 | 2024 | 2677 | 6.570 |
Why?
|
Macular Edema | 35 | 2022 | 374 | 6.460 |
Why?
|
Angiogenesis Inhibitors | 58 | 2024 | 2047 | 6.280 |
Why?
|
Recombinant Fusion Proteins | 40 | 2024 | 3725 | 5.930 |
Why?
|
Geographic Atrophy | 13 | 2024 | 91 | 5.620 |
Why?
|
Intravitreal Injections | 53 | 2024 | 385 | 5.570 |
Why?
|
Choroidal Neovascularization | 26 | 2023 | 364 | 4.910 |
Why?
|
Diabetic Retinopathy | 19 | 2022 | 1274 | 3.300 |
Why?
|
Retinal Vasculitis | 5 | 2023 | 46 | 3.130 |
Why?
|
Tomography, Optical Coherence | 44 | 2024 | 2923 | 2.650 |
Why?
|
Vitreous Body | 17 | 2020 | 399 | 2.390 |
Why?
|
Fluorescein Angiography | 38 | 2024 | 1062 | 2.320 |
Why?
|
Vascular Endothelial Growth Factor A | 38 | 2024 | 3493 | 2.310 |
Why?
|
Macula Lutea | 6 | 2019 | 177 | 2.300 |
Why?
|
Retinal Vein Occlusion | 14 | 2019 | 149 | 2.200 |
Why?
|
Eye Diseases | 7 | 2024 | 653 | 1.910 |
Why?
|
Vitrectomy | 13 | 2017 | 392 | 1.880 |
Why?
|
Laser Coagulation | 14 | 2019 | 330 | 1.860 |
Why?
|
Subretinal Fluid | 5 | 2022 | 24 | 1.680 |
Why?
|
Lasers, Solid-State | 3 | 2020 | 176 | 1.580 |
Why?
|
Endophthalmitis | 5 | 2020 | 260 | 1.250 |
Why?
|
Retinal Detachment | 7 | 2016 | 429 | 1.150 |
Why?
|
Retinal Diseases | 7 | 2024 | 705 | 1.150 |
Why?
|
Vision Disorders | 8 | 2020 | 1088 | 1.130 |
Why?
|
Fundus Oculi | 15 | 2021 | 557 | 1.080 |
Why?
|
Retinal Hemorrhage | 2 | 2018 | 95 | 1.060 |
Why?
|
Double-Blind Method | 40 | 2024 | 12341 | 1.050 |
Why?
|
Retina | 17 | 2022 | 2656 | 1.020 |
Why?
|
Ophthalmic Solutions | 6 | 2022 | 312 | 0.960 |
Why?
|
Cataract Extraction | 7 | 2018 | 467 | 0.950 |
Why?
|
Angiopoietin-2 | 2 | 2024 | 173 | 0.940 |
Why?
|
Laser Therapy | 4 | 2020 | 1094 | 0.910 |
Why?
|
Myopia, Degenerative | 2 | 2015 | 14 | 0.870 |
Why?
|
Antibodies, Bispecific | 2 | 2024 | 196 | 0.830 |
Why?
|
Hawks | 1 | 2022 | 1 | 0.830 |
Why?
|
Angioid Streaks | 2 | 2013 | 14 | 0.810 |
Why?
|
Angiopoietins | 1 | 2021 | 86 | 0.710 |
Why?
|
Retinal Artery Occlusion | 1 | 2020 | 77 | 0.690 |
Why?
|
Medical Futility | 1 | 2020 | 136 | 0.630 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 1 | 2019 | 183 | 0.630 |
Why?
|
Treatment Outcome | 58 | 2024 | 64670 | 0.610 |
Why?
|
Immunoglobulin Fab Fragments | 1 | 2020 | 445 | 0.600 |
Why?
|
Antibodies, Monoclonal | 14 | 2022 | 9185 | 0.600 |
Why?
|
Integrins | 1 | 2022 | 834 | 0.600 |
Why?
|
Diabetes Mellitus | 5 | 2022 | 5841 | 0.580 |
Why?
|
Parvovirinae | 1 | 2017 | 10 | 0.580 |
Why?
|
Vitreoretinopathy, Proliferative | 2 | 2016 | 76 | 0.580 |
Why?
|
Aged | 82 | 2024 | 169266 | 0.570 |
Why?
|
Retinal Vessels | 2 | 2021 | 854 | 0.570 |
Why?
|
Aged, 80 and over | 49 | 2024 | 58946 | 0.560 |
Why?
|
Endoscopes | 2 | 2014 | 169 | 0.540 |
Why?
|
Ocular Hypotension | 1 | 2016 | 23 | 0.530 |
Why?
|
Central Serous Chorioretinopathy | 1 | 2016 | 27 | 0.530 |
Why?
|
Humans | 147 | 2024 | 761098 | 0.530 |
Why?
|
Sickness Impact Profile | 8 | 2020 | 299 | 0.520 |
Why?
|
Follow-Up Studies | 31 | 2024 | 39121 | 0.520 |
Why?
|
Retreatment | 9 | 2013 | 598 | 0.500 |
Why?
|
Vancomycin | 1 | 2018 | 503 | 0.490 |
Why?
|
Venous Pressure | 1 | 2015 | 55 | 0.490 |
Why?
|
Basement Membrane | 1 | 2016 | 348 | 0.490 |
Why?
|
Eye Infections | 1 | 2015 | 62 | 0.490 |
Why?
|
Lenses, Intraocular | 2 | 2015 | 139 | 0.490 |
Why?
|
Albinism, Oculocutaneous | 1 | 2015 | 19 | 0.490 |
Why?
|
Photochemotherapy | 5 | 2015 | 826 | 0.490 |
Why?
|
Iris Diseases | 1 | 2015 | 37 | 0.480 |
Why?
|
Hypopigmentation | 1 | 2015 | 43 | 0.480 |
Why?
|
Valsalva Maneuver | 1 | 2015 | 99 | 0.480 |
Why?
|
MAP Kinase Kinase 1 | 1 | 2016 | 332 | 0.470 |
Why?
|
Pigment Epithelium of Eye | 1 | 2015 | 209 | 0.470 |
Why?
|
Fovea Centralis | 3 | 2012 | 126 | 0.470 |
Why?
|
Drug Substitution | 2 | 2016 | 291 | 0.460 |
Why?
|
Retinal Perforations | 4 | 2018 | 138 | 0.460 |
Why?
|
Male | 93 | 2024 | 360675 | 0.460 |
Why?
|
Retinal Neovascularization | 1 | 2017 | 288 | 0.450 |
Why?
|
Pseudoxanthoma Elasticum | 1 | 2013 | 14 | 0.450 |
Why?
|
Emphysema | 1 | 2016 | 238 | 0.440 |
Why?
|
Vitelliform Macular Dystrophy | 1 | 2013 | 18 | 0.440 |
Why?
|
Female | 91 | 2024 | 392458 | 0.410 |
Why?
|
Vitreous Detachment | 3 | 2018 | 22 | 0.410 |
Why?
|
Vascular Endothelial Growth Factors | 2 | 2013 | 748 | 0.400 |
Why?
|
Endotamponade | 4 | 2016 | 37 | 0.400 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 5 | 2009 | 2270 | 0.390 |
Why?
|
Cryosurgery | 2 | 2016 | 474 | 0.390 |
Why?
|
Early Diagnosis | 1 | 2017 | 1187 | 0.390 |
Why?
|
Phenyl Ethers | 2 | 2024 | 62 | 0.380 |
Why?
|
Propanolamines | 2 | 2024 | 163 | 0.370 |
Why?
|
Benzimidazoles | 1 | 2016 | 858 | 0.370 |
Why?
|
Porphyrins | 3 | 2009 | 352 | 0.360 |
Why?
|
Visual Field Tests | 7 | 2022 | 410 | 0.360 |
Why?
|
Middle Aged | 60 | 2024 | 220835 | 0.350 |
Why?
|
Endoscopy | 3 | 2016 | 1852 | 0.350 |
Why?
|
Histoplasmosis | 1 | 2010 | 63 | 0.350 |
Why?
|
Bromobenzenes | 1 | 2009 | 2 | 0.350 |
Why?
|
Choroid | 2 | 2024 | 363 | 0.340 |
Why?
|
Benzeneacetamides | 1 | 2009 | 36 | 0.340 |
Why?
|
Phenylacetates | 1 | 2009 | 111 | 0.340 |
Why?
|
Benzophenones | 1 | 2009 | 57 | 0.330 |
Why?
|
Intraocular Pressure | 9 | 2020 | 1295 | 0.330 |
Why?
|
Disease Management | 1 | 2020 | 2508 | 0.330 |
Why?
|
Ketorolac | 1 | 2009 | 94 | 0.320 |
Why?
|
Uveitis, Anterior | 2 | 2000 | 101 | 0.320 |
Why?
|
Prospective Studies | 30 | 2024 | 54419 | 0.310 |
Why?
|
Photosensitizing Agents | 3 | 2009 | 625 | 0.310 |
Why?
|
Ketorolac Tromethamine | 3 | 2008 | 21 | 0.310 |
Why?
|
Cost Savings | 1 | 2013 | 912 | 0.300 |
Why?
|
Protein Kinase Inhibitors | 1 | 2024 | 5662 | 0.290 |
Why?
|
Phacoemulsification | 3 | 2010 | 150 | 0.290 |
Why?
|
Glucocorticoids | 5 | 2014 | 2160 | 0.280 |
Why?
|
Exercise Test | 1 | 2015 | 2165 | 0.280 |
Why?
|
Cataract | 2 | 2012 | 832 | 0.270 |
Why?
|
Dinoprostone | 1 | 2009 | 597 | 0.270 |
Why?
|
Silicone Oils | 2 | 2016 | 22 | 0.270 |
Why?
|
Fibrinolysin | 2 | 2018 | 130 | 0.260 |
Why?
|
Dose-Response Relationship, Drug | 9 | 2024 | 10755 | 0.260 |
Why?
|
Vitreoretinal Surgery | 2 | 2016 | 28 | 0.250 |
Why?
|
Prednisolone | 2 | 2008 | 324 | 0.240 |
Why?
|
Scleral Buckling | 2 | 2016 | 95 | 0.230 |
Why?
|
Injections, Intraocular | 2 | 2024 | 33 | 0.230 |
Why?
|
Anti-Bacterial Agents | 2 | 2018 | 7405 | 0.220 |
Why?
|
Retinal Pigment Epithelium | 2 | 2021 | 303 | 0.210 |
Why?
|
Sulfur Hexafluoride | 2 | 2013 | 26 | 0.210 |
Why?
|
Dexamethasone | 3 | 2011 | 1945 | 0.210 |
Why?
|
Miosis | 2 | 2015 | 9 | 0.200 |
Why?
|
Color Vision | 1 | 2022 | 23 | 0.200 |
Why?
|
Plasma Kallikrein | 1 | 2021 | 21 | 0.200 |
Why?
|
Drug Implants | 3 | 2011 | 230 | 0.190 |
Why?
|
Monitoring, Ambulatory | 2 | 2016 | 355 | 0.190 |
Why?
|
Injections | 10 | 2010 | 832 | 0.190 |
Why?
|
Peptides, Cyclic | 1 | 2023 | 392 | 0.190 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2024 | 636 | 0.190 |
Why?
|
Glaucoma | 1 | 2011 | 1186 | 0.190 |
Why?
|
Pseudophakia | 1 | 2000 | 60 | 0.180 |
Why?
|
Visual Fields | 4 | 2016 | 1059 | 0.180 |
Why?
|
Drug Administration Schedule | 3 | 2022 | 4849 | 0.180 |
Why?
|
Hyperthermia, Induced | 1 | 2004 | 417 | 0.170 |
Why?
|
Tromethamine | 1 | 1999 | 31 | 0.160 |
Why?
|
Tolmetin | 1 | 1999 | 24 | 0.160 |
Why?
|
Complement Inactivating Agents | 1 | 2019 | 53 | 0.160 |
Why?
|
Adult | 23 | 2024 | 221083 | 0.160 |
Why?
|
Retinal Vein | 1 | 2019 | 47 | 0.160 |
Why?
|
Time Factors | 8 | 2020 | 39953 | 0.160 |
Why?
|
Eye Pain | 2 | 2016 | 46 | 0.160 |
Why?
|
Drug Combinations | 2 | 2016 | 2048 | 0.160 |
Why?
|
Postoperative Complications | 3 | 2018 | 15634 | 0.160 |
Why?
|
Prostaglandins F, Synthetic | 1 | 1998 | 32 | 0.150 |
Why?
|
Retrospective Studies | 18 | 2020 | 80673 | 0.150 |
Why?
|
Drug Therapy, Combination | 4 | 2019 | 6305 | 0.150 |
Why?
|
Complement C3 | 1 | 2019 | 434 | 0.140 |
Why?
|
Inflammation | 2 | 2023 | 10758 | 0.140 |
Why?
|
Drug Approval | 1 | 2024 | 812 | 0.140 |
Why?
|
Fluorocarbons | 2 | 2013 | 492 | 0.140 |
Why?
|
Neurofibroma, Plexiform | 1 | 2017 | 66 | 0.140 |
Why?
|
Exudates and Transudates | 2 | 2014 | 174 | 0.130 |
Why?
|
Air | 1 | 2016 | 187 | 0.130 |
Why?
|
United States Food and Drug Administration | 1 | 2024 | 1661 | 0.130 |
Why?
|
Isoindoles | 1 | 2015 | 35 | 0.130 |
Why?
|
Administration, Topical | 3 | 2009 | 703 | 0.130 |
Why?
|
Receptor-Like Protein Tyrosine Phosphatases, Class 3 | 1 | 2014 | 25 | 0.120 |
Why?
|
Administration, Oral | 2 | 2020 | 4014 | 0.120 |
Why?
|
Immunocompetence | 1 | 1995 | 138 | 0.120 |
Why?
|
Drug Compounding | 1 | 2016 | 245 | 0.120 |
Why?
|
Magnetic Resonance Angiography | 1 | 2021 | 1432 | 0.120 |
Why?
|
Sulfonic Acids | 1 | 2014 | 102 | 0.120 |
Why?
|
Receptor, TIE-2 | 1 | 2014 | 176 | 0.110 |
Why?
|
Exophthalmos | 1 | 1995 | 97 | 0.110 |
Why?
|
Eye Infections, Fungal | 1 | 1995 | 100 | 0.110 |
Why?
|
Carotid Stenosis | 1 | 2021 | 859 | 0.110 |
Why?
|
Europe | 1 | 2020 | 3422 | 0.110 |
Why?
|
Peptide Fragments | 2 | 2018 | 5103 | 0.110 |
Why?
|
Antineoplastic Agents | 1 | 2016 | 13630 | 0.110 |
Why?
|
Incidence | 6 | 2020 | 21357 | 0.110 |
Why?
|
Surgical Wound Dehiscence | 1 | 1994 | 212 | 0.110 |
Why?
|
Hospitals, Military | 1 | 1993 | 62 | 0.110 |
Why?
|
Ankyrin Repeat | 1 | 2012 | 19 | 0.110 |
Why?
|
Chronic Disease | 3 | 2016 | 9317 | 0.110 |
Why?
|
Telemedicine | 3 | 2016 | 3051 | 0.110 |
Why?
|
Prognosis | 5 | 2020 | 29672 | 0.100 |
Why?
|
Biological Availability | 2 | 2012 | 389 | 0.100 |
Why?
|
Neoplasms | 2 | 2024 | 22125 | 0.100 |
Why?
|
Dependovirus | 1 | 2017 | 712 | 0.100 |
Why?
|
Neurofibromatosis 1 | 1 | 2017 | 561 | 0.100 |
Why?
|
Mycoses | 1 | 1995 | 386 | 0.100 |
Why?
|
Indocyanine Green | 1 | 2013 | 233 | 0.100 |
Why?
|
Eye Injuries, Penetrating | 1 | 1993 | 124 | 0.090 |
Why?
|
Eye Injuries | 2 | 2010 | 227 | 0.090 |
Why?
|
Ciliary Neurotrophic Factor | 1 | 2011 | 77 | 0.090 |
Why?
|
Anesthesia, Local | 1 | 2013 | 277 | 0.090 |
Why?
|
Coloring Agents | 1 | 2013 | 562 | 0.090 |
Why?
|
United States | 6 | 2024 | 72337 | 0.090 |
Why?
|
Anti-Inflammatory Agents | 1 | 2000 | 1812 | 0.090 |
Why?
|
Ophthalmoscopy | 1 | 2011 | 171 | 0.090 |
Why?
|
Lens Implantation, Intraocular | 3 | 2008 | 191 | 0.090 |
Why?
|
Disease Progression | 5 | 2020 | 13506 | 0.090 |
Why?
|
Blast Injuries | 2 | 2010 | 322 | 0.090 |
Why?
|
Ligaments | 1 | 2010 | 127 | 0.090 |
Why?
|
Suture Techniques | 1 | 1994 | 768 | 0.080 |
Why?
|
Treatment Failure | 1 | 2016 | 2643 | 0.080 |
Why?
|
Integrin alpha5beta1 | 1 | 2009 | 36 | 0.080 |
Why?
|
Tamoxifen | 1 | 1994 | 965 | 0.080 |
Why?
|
Lenses | 2 | 2008 | 42 | 0.080 |
Why?
|
Eye Proteins | 1 | 2013 | 632 | 0.080 |
Why?
|
Emergency Medical Technicians | 1 | 2010 | 119 | 0.080 |
Why?
|
Exfoliation Syndrome | 1 | 2010 | 113 | 0.080 |
Why?
|
Aniline Compounds | 1 | 2014 | 1073 | 0.080 |
Why?
|
Propionates | 1 | 2009 | 181 | 0.080 |
Why?
|
Drug Delivery Systems | 1 | 2000 | 2223 | 0.080 |
Why?
|
Equipment Design | 2 | 2014 | 3509 | 0.080 |
Why?
|
Diabetes Mellitus, Type 1 | 5 | 2015 | 3416 | 0.070 |
Why?
|
Single-Blind Method | 2 | 2013 | 1577 | 0.070 |
Why?
|
Costs and Cost Analysis | 1 | 2013 | 1664 | 0.070 |
Why?
|
Pyrrolidines | 1 | 2009 | 339 | 0.070 |
Why?
|
Drug Costs | 1 | 2016 | 1183 | 0.070 |
Why?
|
Genetic Vectors | 1 | 2017 | 3388 | 0.070 |
Why?
|
Drug Resistance | 1 | 2013 | 1594 | 0.070 |
Why?
|
Longitudinal Studies | 2 | 2022 | 14607 | 0.070 |
Why?
|
Genetic Markers | 1 | 2013 | 2599 | 0.070 |
Why?
|
Peptides | 2 | 2022 | 4353 | 0.070 |
Why?
|
Microsurgery | 1 | 2011 | 793 | 0.060 |
Why?
|
Sinusitis | 1 | 1995 | 991 | 0.060 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2009 | 1535 | 0.060 |
Why?
|
Eye Infections, Bacterial | 1 | 2008 | 242 | 0.060 |
Why?
|
Tissue Distribution | 1 | 2009 | 2262 | 0.060 |
Why?
|
Health Education | 1 | 2012 | 1049 | 0.060 |
Why?
|
Diagnosis, Differential | 3 | 2015 | 12975 | 0.060 |
Why?
|
Piperazines | 1 | 2015 | 2522 | 0.060 |
Why?
|
DEAE-Dextran | 1 | 2024 | 9 | 0.060 |
Why?
|
Atrophy | 1 | 2009 | 1633 | 0.060 |
Why?
|
Streptococcal Infections | 1 | 2008 | 617 | 0.060 |
Why?
|
Enzyme Inhibitors | 1 | 2014 | 3700 | 0.060 |
Why?
|
Fibrinolytic Agents | 1 | 2013 | 2075 | 0.060 |
Why?
|
Prosthesis Implantation | 1 | 2008 | 591 | 0.060 |
Why?
|
Optics and Photonics | 1 | 2005 | 306 | 0.060 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2009 | 1784 | 0.060 |
Why?
|
Practice Guidelines as Topic | 2 | 2024 | 7400 | 0.060 |
Why?
|
Pyrimidines | 1 | 2015 | 3026 | 0.050 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 5494 | 0.050 |
Why?
|
Miniaturization | 3 | 2008 | 153 | 0.050 |
Why?
|
Mass Spectrometry | 1 | 2009 | 2189 | 0.050 |
Why?
|
Calcaneus | 1 | 2004 | 142 | 0.050 |
Why?
|
Fibrosis | 1 | 2009 | 2051 | 0.050 |
Why?
|
Lipoma | 1 | 2004 | 293 | 0.050 |
Why?
|
Ophthalmic Artery | 1 | 2021 | 58 | 0.050 |
Why?
|
Orbit | 2 | 1995 | 457 | 0.050 |
Why?
|
Neurofibromin 2 | 1 | 2022 | 269 | 0.050 |
Why?
|
Emergency Medicine | 1 | 2010 | 1198 | 0.050 |
Why?
|
Health Care Costs | 1 | 2013 | 3238 | 0.040 |
Why?
|
Reoperation | 3 | 2016 | 4304 | 0.040 |
Why?
|
Cross-Over Studies | 1 | 2006 | 2081 | 0.040 |
Why?
|
Staphylococcal Infections | 1 | 2008 | 1400 | 0.040 |
Why?
|
Blood-Retinal Barrier | 1 | 2019 | 62 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2016 | 10213 | 0.040 |
Why?
|
Carotid Artery, Internal | 1 | 2021 | 445 | 0.040 |
Why?
|
Genotype | 1 | 2013 | 12983 | 0.040 |
Why?
|
Anterior Chamber | 1 | 1999 | 194 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 5 | 2015 | 12145 | 0.040 |
Why?
|
Research Design | 1 | 2014 | 6178 | 0.040 |
Why?
|
Pyridines | 1 | 2009 | 2872 | 0.040 |
Why?
|
Signal Transduction | 1 | 2021 | 23415 | 0.040 |
Why?
|
Blood Flow Velocity | 1 | 2021 | 1374 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 3 | 2016 | 20600 | 0.030 |
Why?
|
Carotid Arteries | 1 | 2021 | 941 | 0.030 |
Why?
|
Candida albicans | 1 | 2000 | 372 | 0.030 |
Why?
|
False Positive Reactions | 2 | 2012 | 958 | 0.030 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2011 | 4013 | 0.030 |
Why?
|
Acute Disease | 2 | 2011 | 7240 | 0.030 |
Why?
|
Quality of Life | 5 | 2023 | 13362 | 0.030 |
Why?
|
Middle East | 2 | 1993 | 231 | 0.030 |
Why?
|
Capillaries | 1 | 2019 | 755 | 0.030 |
Why?
|
Mitosporic Fungi | 1 | 1995 | 17 | 0.030 |
Why?
|
Capillary Permeability | 1 | 2019 | 773 | 0.030 |
Why?
|
Endothelium, Corneal | 2 | 2008 | 216 | 0.030 |
Why?
|
Phenotype | 1 | 2013 | 16572 | 0.030 |
Why?
|
Aspergillus | 1 | 1995 | 94 | 0.030 |
Why?
|
Iatrogenic Disease | 1 | 1998 | 539 | 0.030 |
Why?
|
Serotonin Receptor Agonists | 1 | 2015 | 151 | 0.030 |
Why?
|
Safety | 1 | 1999 | 1151 | 0.030 |
Why?
|
Cell Count | 2 | 2008 | 1831 | 0.030 |
Why?
|
Crystallization | 1 | 1994 | 528 | 0.030 |
Why?
|
Injections, Subcutaneous | 1 | 2014 | 672 | 0.030 |
Why?
|
Predictive Value of Tests | 3 | 2012 | 15308 | 0.030 |
Why?
|
Complement Factor H | 1 | 2013 | 110 | 0.030 |
Why?
|
Paranasal Sinuses | 1 | 1995 | 265 | 0.030 |
Why?
|
Tissue Adhesions | 1 | 2013 | 218 | 0.030 |
Why?
|
Aqueous Humor | 1 | 2012 | 153 | 0.020 |
Why?
|
Light | 1 | 1998 | 1351 | 0.020 |
Why?
|
Office Visits | 1 | 2016 | 594 | 0.020 |
Why?
|
Sclerostomy | 1 | 2011 | 16 | 0.020 |
Why?
|
Nasal Mucosa | 1 | 1995 | 415 | 0.020 |
Why?
|
Bone Neoplasms | 1 | 2004 | 2527 | 0.020 |
Why?
|
Animals | 2 | 2022 | 168083 | 0.020 |
Why?
|
Glaucoma, Open-Angle | 1 | 1998 | 739 | 0.020 |
Why?
|
Case Management | 1 | 2013 | 272 | 0.020 |
Why?
|
Clinical Trials as Topic | 2 | 2023 | 8000 | 0.020 |
Why?
|
Apolipoproteins | 1 | 2013 | 327 | 0.020 |
Why?
|
Radiation Injuries | 1 | 1998 | 1191 | 0.020 |
Why?
|
Capsules | 1 | 2011 | 191 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2000 | 6067 | 0.020 |
Why?
|
Cadaver | 1 | 1994 | 1358 | 0.020 |
Why?
|
Maximum Tolerated Dose | 1 | 2012 | 883 | 0.020 |
Why?
|
Disease Models, Animal | 1 | 2009 | 18217 | 0.020 |
Why?
|
Antifungal Agents | 1 | 1995 | 753 | 0.020 |
Why?
|
Complement System Proteins | 1 | 2013 | 737 | 0.020 |
Why?
|
Explosions | 1 | 2010 | 107 | 0.020 |
Why?
|
Epiretinal Membrane | 1 | 2009 | 73 | 0.020 |
Why?
|
Streptococcus mitis | 1 | 2008 | 7 | 0.020 |
Why?
|
Viridans Streptococci | 1 | 2008 | 16 | 0.020 |
Why?
|
Sensory Aids | 1 | 2008 | 40 | 0.020 |
Why?
|
Pain, Postoperative | 1 | 1999 | 1738 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2019 | 5249 | 0.020 |
Why?
|
Staphylococcus epidermidis | 1 | 2008 | 123 | 0.020 |
Why?
|
Sensitivity and Specificity | 3 | 2012 | 14676 | 0.020 |
Why?
|
Absorbable Implants | 1 | 2010 | 338 | 0.020 |
Why?
|
Vision, Ocular | 1 | 2011 | 454 | 0.020 |
Why?
|
Premedication | 1 | 2008 | 246 | 0.020 |
Why?
|
Risk Factors | 5 | 2014 | 74219 | 0.020 |
Why?
|
Terrorism | 1 | 2010 | 210 | 0.020 |
Why?
|
Endpoint Determination | 1 | 2010 | 590 | 0.020 |
Why?
|
Emergencies | 1 | 1993 | 1217 | 0.020 |
Why?
|
Contrast Sensitivity | 1 | 2008 | 253 | 0.020 |
Why?
|
Ultrasonography | 1 | 2000 | 5971 | 0.020 |
Why?
|
Fibronectins | 1 | 2009 | 724 | 0.020 |
Why?
|
Equipment Safety | 1 | 2006 | 249 | 0.020 |
Why?
|
Pilot Projects | 2 | 2011 | 8639 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 3803 | 0.020 |
Why?
|
Registries | 1 | 2020 | 8236 | 0.010 |
Why?
|
Military Personnel | 1 | 1993 | 1246 | 0.010 |
Why?
|
Intraoperative Complications | 1 | 2010 | 1165 | 0.010 |
Why?
|
Wound Healing | 1 | 1994 | 2801 | 0.010 |
Why?
|
Rabbits | 1 | 2009 | 4749 | 0.010 |
Why?
|
Equipment Failure Analysis | 1 | 2005 | 846 | 0.010 |
Why?
|
Cell Adhesion | 1 | 2009 | 3090 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2023 | 26187 | 0.010 |
Why?
|
Photography | 1 | 2005 | 532 | 0.010 |
Why?
|
Optic Disk | 1 | 2006 | 421 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2013 | 8519 | 0.010 |
Why?
|
Reproducibility of Results | 2 | 2013 | 20120 | 0.010 |
Why?
|
Protein Binding | 1 | 2012 | 9300 | 0.010 |
Why?
|
Physical Therapy Modalities | 1 | 2004 | 531 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2009 | 5870 | 0.010 |
Why?
|
Blood Pressure | 1 | 2014 | 8478 | 0.010 |
Why?
|
Prosthesis Design | 1 | 2005 | 2115 | 0.010 |
Why?
|
Proteins | 1 | 2013 | 5993 | 0.010 |
Why?
|
Cell Movement | 1 | 2009 | 5195 | 0.010 |
Why?
|
Postoperative Care | 1 | 2004 | 1469 | 0.010 |
Why?
|
Anterior Eye Segment | 1 | 1998 | 143 | 0.010 |
Why?
|
Activities of Daily Living | 1 | 2006 | 2420 | 0.010 |
Why?
|
Prevalence | 1 | 1994 | 15717 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2009 | 11066 | 0.010 |
Why?
|
Cell Line | 1 | 2009 | 15542 | 0.010 |
Why?
|
Aging | 1 | 2014 | 8701 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2009 | 10421 | 0.010 |
Why?
|
Recurrence | 1 | 2006 | 8456 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2013 | 15915 | 0.010 |
Why?
|
Hospitalization | 1 | 1993 | 10712 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2006 | 15845 | 0.000 |
Why?
|
Breast Neoplasms | 1 | 1994 | 20981 | 0.000 |
Why?
|
Magnetic Resonance Imaging | 1 | 2004 | 36418 | 0.000 |
Why?
|
Infant | 1 | 1993 | 36164 | 0.000 |
Why?
|
Child, Preschool | 1 | 1993 | 42217 | 0.000 |
Why?
|
Child | 1 | 1993 | 80134 | 0.000 |
Why?
|
Adolescent | 1 | 1993 | 88271 | 0.000 |
Why?
|